We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Clinical trial applications that need expert advice from a specialist group or committee.
These reports explain our assessment of the scientific evidence used to lead to regulatory decisions on the safety of medicines or medicines classes.
As with any medicine, the MHRA will keep the safety and effectiveness of fluticasone propionate under close review.
Applications received to amend the specification of a patent under sections 27 and 75 before the court and the Office.
Information about new applications, post-licensing, advertising, product information and fees.
Information about the reproductive risks of taking valproate medicines and the measures in place to reduce potential harm.
Product defect recall alert for Folltropin 700 IU Powder and Solvent for Solution for Injection by Vetoquinol SA and Vetoquinol UK Limited.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).